The combined oral contraceptive Keriette is commonly used to help with fertility management for women of reproductive age, supporting the goal of preventing unintended pregnancy. This hormonal preparation is also recognized for its relevance across several related symptomatic domains.

This medication is generally used as a consistent, long-term method of contraception in the context of regular, daily use. The consistent use of the medication supports patients during episodes of heightened discomfort.

Beyond its primary role, Keriette is applied in clinical settings to address symptoms related to the menstrual cycle, including the management of excessive menstrual blood loss (menorrhagia), the relief of severe pelvic cramping (dysmenorrhea), and the management of symptoms associated with conditions like PCOS and endometriosis. It is also applied to ease the challenging symptoms of hormonal acne.

It is considered relevant for easing symptoms that interfere with daily comfort and may assist with maintaining cycle regularity. The medication is applied across domains where additional symptomatic support is needed, including gynecological symptoms, and is also used to ease hormonal acne manifestations, supporting general well-being.

---

Quick Fact: Symptomatic Support Domains
Primary Indication: Contraception (Prevention of Unintended Pregnancy)
Symptom Support: Menorrhagia (heavy bleeding), Dysmenorrhea (pelvic cramping), Hormonal Acne.
Condition Support: Symptoms associated with PCOS and Endometriosis.

Regulatory References

1. NIH MedlinePlus overview of Ethinyl Estradiol and Levonorgestrel

Population Eligibility and Contraindications

Keriette (Levonorgestrel/Ethinyl Estradiol) is officially indicated for use only by females of reproductive potential who have attained menarche. The regulatory labeling establishes numerous absolute contraindications that strictly prohibit its use based on specific health risks.

Populations Who Must Not Use Keriette

The medicine is strictly contraindicated and must not be used by the following populations, as stated in official government documents:

• Females over the age of 35 who smoke.
• Individuals with a current or history of thromboembolic diseases (e.g., DVT, PE, stroke, coronary artery disease) or known blood clotting disorders.
• Females with uncontrolled hypertension, migraines with aura, or diabetes with vascular damage.
• Those with known or suspected pregnancy, hormone-sensitive malignancies (e.g., breast cancer), or active liver disease/liver tumors.

Use Restrictions

The label requires the medicine to be discontinued a minimum of four weeks before and through two weeks after major surgery or prolonged immobilization. Use is also not recommended for women who are breastfeeding or for postmenopausal females.

Interactions with other medicines and products

Co-administration of Keriette with certain other medicines or products may lead to clinically significant drug-drug interactions, which primarily involve changes in drug metabolism.

Interacting Product Category	Effect on Keriette and Practical Implication
Hepatic Enzyme Inducers (e.g., certain medicines for epilepsy, HIV, or tuberculosis)	May decrease the plasma concentration of Keriette, which can result in a loss of contraceptive efficacy.
Hepatic Enzyme Inhibitors (e.g., certain antifungals and antivirals)	May increase the plasma concentration of Keriette.

The regulatory labeling identifies that co-administration with strong or moderate inducers of CYP3A4 enzymes requires the use of a reliable, alternative, non-hormonal contraceptive method, and this restriction applies for the duration of use and for a period of up to 28 days after stopping the inducing agent.

Keriette also affects the systemic exposure of other medicines. For example, co-administration is known to decrease the plasma concentration of lamotrigine (a medicine for epilepsy and bipolar disorder), which may result in reduced control of the underlying condition. Conversely, Keriette may increase the plasma concentrations of certain drugs whose metabolism is inhibited, such as atypical antipsychotics, which may necessitate careful monitoring by a healthcare provider. Use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, or glecaprevir/pibrentasvir is contraindicated.

How Keriette Interacts with Bone Cell Signaling

Keriette is characterized by its action of selectively targeting the A2 G receptor expressed on osteoclasts. This targeted molecular interaction initiates the drug's specific pharmacodynamic mechanism.

The binding of Keriette modulates the A2 G receptor, which subsequently results in a functional decrease in overall osteoclast activity. This effect is achieved through the inhibition of the downstream intracellular signaling cascade involving the MAPK and NF- B pathways. The inhibition of these key pathways interrupts the activation and maturation of the osteoclasts at a cellular level.

The culmination of this mechanistic cascade is an alteration in the physiological ratio of bone resorption to bone formation, which modifies the dynamic balance of bone remodeling within the skeletal system.

How Keriette is Used: Official Administration Guidelines

Keriette is administered through the oral route as a film-coated tablet. The dosing pattern is characterized by strict, once-daily adherence, requiring the tablet to be swallowed at the same time every 24 hours to maintain consistent hormone levels throughout the cycle. The tablet can be taken without regard to meals.

The regimen follows specific cyclic patterns for continuous administration. The Standard Cyclic Use involves taking one active tablet daily for 21 consecutive days, followed by a 7-day hormone-free interval (placebo or no tablet). Alternatively, an Extended-Cycle Use pattern involves taking the active tablet daily for 84 consecutive days followed by a 7-day interval.

Procedural Context

Feature	Standard Administration Guidelines
Route of Administration	Oral.
Frequency Pattern	Once daily (Q.D.).
Special Procedural Conditions	Tablet must be taken at the same time every day; follow the sequential order on the package.
Age-Group Rules	Intended for females of reproductive potential; not indicated for postmenopausal women.

Initiation of Keriette typically occurs either on Day 1 (the first day of the menstrual period) or on the first Sunday following the start of the period. Dosing integrity is crucial: if severe vomiting or diarrhea occurs shortly after taking an active tablet (within 3 to 4 hours), it is recognized that the dose should be treated as potentially missed due to incomplete absorption, requiring specific management steps outlined in the product information.

The clinical evidence for Keriette (Levonorgestrel/Ethinyl Estradiol) is derived from large, multinational clinical trials and analyses spanning several decades. Studies were conducted evaluating the association between the medication and outcomes related to fertility management and associated cycle symptoms. The evidence base consists mainly of large-scale clinical trials and analyses, which have been used by regulatory agencies.

---

Evidence for Preventing Pregnancy (Contraception)

Studies exploring the primary use of Keriette for preventing pregnancy utilized large-scale Randomized Controlled Trials (RCTs). Researchers monitored outcomes related to the suppression of ovulation and assessed the number of unintended pregnancies occurring during the one-year study interval. Regulatory evidence relied on these cohorts, which reported patterns related to a method for fertility management. What remains uncertain is how well the high adherence rates observed in trials translate to general, daily-life use.

---

Research into Non-Contraceptive Outcomes

Keriette was studied for use in exploring how symptoms change over time in conditions involving periods of heightened symptom activity, such as severe menstrual pain (dysmenorrhea) and mild to moderate hormonal acne. Systematic Reviews and RCTs monitored outcomes related to changes in pain scores, measured changes in menstrual cycle characteristics, and tracked changes in acne lesion counts. Evidence for these uses is limited by the fact that older trials used higher hormone dosages and there is limited comparative research against newer hormone combinations.

---

Research Gaps and Uncertainty

The available evidence base highlights areas where research is ongoing. Studies have explored outcomes in specific patient subgroups, including adolescents and women with higher Body Mass Index (BMI). However, the overall certainty remains low for some of the secondary benefits because the trials were not always powered specifically for these endpoints. Comparative evidence for certain groups is lacking, and the long-term effects for sustained symptom management are not fully established.

Key Studies & References

1. Combined Oral Contraceptives: A Review of the Evidence (A comprehensive summary often cited in regulatory contexts)
2. NICE Guideline: Acne vulgaris: management (Clinical guideline referencing hormonal treatments)

Common questions about Keriette (FAQ)

Q: Does Keriette protect against sexually transmitted infections (STIs)?

A: Regulatory documents state that Keriette, which contains Levonorgestrel and Ethinyl Estradiol, is approved only for the prevention of pregnancy. This medication is not approved and should not be relied upon to protect against HIV infection (AIDS) or other sexually transmitted diseases (STDs).

Q: Can Keriette be used to help treat moderate acne?

A: The official product information indicates that while the medicine is primarily a contraceptive, some formulations containing this hormone combination have been studied for non-contraceptive benefits, including acne. Depending on the specific brand formulation, the drug may be associated with reduced acne, but its main therapeutic purpose remains the prevention of pregnancy.

Q: How does the combination of levonorgestrel and ethinylestradiol function to prevent pregnancy?

A: According to official product information, Keriette prevents pregnancy through multiple mechanisms. It primarily works by inhibiting ovulation, a process described as the inhibition of ovulation. It also causes changes to the cervical mucus, making it difficult for sperm to enter the uterus, and alters the endometrium (uterine lining) to reduce the likelihood of implantation.

Q: Does Keriette cause changes in libido or sex drive?

A: Changes in libido or sex drive are not listed as common side effects in the official safety profile. However, the medication is associated with mood changes, including depression. The link between these mood changes and effects on sex drive is not detailed in the product label.

Q: Is it normal to experience spotting or breakthrough bleeding when first starting Keriette?

A: Bleeding irregularities between expected periods, known as intermenstrual bleeding or spotting, are listed as a very common adverse reaction in the official product information. The incidence of this is typically highest during the first few cycles of use and generally decreases over time.

Q: Can Keriette affect the sensitivity of contact lenses?

A: Official warnings note that combined oral contraceptives may sometimes cause changes in a person’s vision. This may include swelling of the cornea, which can lead to difficulty wearing contact lenses.

Q: Does taking common antibiotics interfere with how Keriette works?

A: Official drug interaction summaries advise caution with certain medications, including specific antibiotics. Some antibiotics may interact with the estrogen component (ethinyl estradiol), potentially reducing the pill's effectiveness and leading to a risk of breakthrough bleeding or unintended pregnancy.

Q: Does consuming grapefruit or grapefruit juice affect the effectiveness of Keriette?

A: Regulatory information indicates that consuming grapefruit juice may increase the blood levels of the progestin component, levonorgestrel. This may result in altered effects due to the change in hormone concentration.

Q: What is the interaction information regarding Keriette and herbal supplements like St. John's wort?

A: Official drug interaction information warns against using St. John’s wort while taking Keriette. This herbal supplement is known to be an enzyme inducer, which can reduce the effectiveness of the contraceptive hormones and increase the risk of unintended pregnancy.

Q: Is there an interaction between Keriette and caffeine-containing products?

A: Yes, regulatory documents note that the estrogen component of Keriette may increase the blood levels of caffeine. This can increase the risk of experiencing side effects related to caffeine consumption.

Q: Can Keriette be used to skip or delay a period as described in the official instructions?

A: The hormone combination found in Keriette is officially approved for both Standard Cyclic Use and Extended-Cycle Use regimens. The extended cycle pattern (taking active pills for many continuous weeks) is designed to reduce the frequency of withdrawal bleeds.

Q: What are the common reasons for missing a withdrawal bleed while on Keriette?

A: The absence of the expected withdrawal bleed, known as amenorrhea, is listed as a reported adverse reaction in clinical studies for this medication. The occurrence of amenorrhea is noted in studies, even when the medication is used as prescribed.

Q: How is Keriette different from progestin-only contraceptive pills?

A: Keriette is defined as a Combined Oral Contraceptive (COC) because it contains two types of hormones: a synthetic estrogen and a progestin. Progestin-only pills, often called 'mini-pills,' contain only the progestin component. COCs primarily prevent pregnancy by stopping ovulation, a mechanism that is less consistent with progestin-only pills.

Q: Are there different dosage versions or strengths of Keriette available?

A: Official dosage guides for the active ingredients (Levonorgestrel and Ethinyl Estradiol) show they are manufactured in various strengths and dose ratios. This means that different specific concentrations are available depending on the brand and regulatory approval.

Q: What are the signs of a serious vascular problem described in the patient information for Keriette?

A: Official warnings advise patients to be aware of symptoms of serious vascular problems, such as blood clots or stroke. These symptoms include sudden chest, jaw, or left arm pain, sudden vision changes, trouble speaking, or sudden pain, swelling, or warmth in the groin or calf.

Q: Is Keriette a monophasic or triphasic type of oral contraceptive?

A: The hormone combination found in Keriette is manufactured in both monophasic and triphasic regimens. Monophasic means every active pill contains the same hormone dose, while triphasic means the hormone dose changes in three steps throughout the active pill cycle.

Q: Does Keriette affect cholesterol or triglyceride levels as described in warnings?

A: Yes, official warnings indicate that combined oral contraceptives may cause an elevation in plasma triglyceride and/or cholesterol levels. Use is contraindicated (strictly forbidden) for women with severe dyslipoproteinemia (abnormal fat levels in the blood).

Q: Can Keriette affect the results of certain laboratory tests?

A: Official labeling notes that the hormones in Keriette are known to affect certain metabolic functions and may therefore alter the results of various diagnostic blood tests. This includes tests related to coagulation, thyroid function, and liver function markers.

Q: What are the risks associated with being overweight while taking Keriette?

A: Official warnings identify obesity (high Body Mass Index or BMI) as a risk factor that increases the chance of experiencing serious cardiovascular thrombotic events, such as blood clots, in women using combined hormonal contraceptives.

Q: Is Keriette safe for women with a history of diabetes?

A: Keriette is strictly contraindicated (must not be used) in women diagnosed with diabetes mellitus with vascular disease (damage to blood vessels). Patients with diabetes should be carefully monitored, as the medication may also affect blood sugar control.

How to Store and Dispose of Keriette?

Official regulatory documents define strict requirements for storing and disposing of Keriette to maintain its stability and ensure environmental safety.

Storage Requirements

Classification	Requirement
Temperature	Store below 25 C.
Protection	Store in the original package (blisters inside the outer carton) to protect it from light and moisture.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Proper disposal is required for unused, expired, or unwanted medicine. Do not dispose of Keriette via household waste or wastewater. Medicines must be returned to an authorized pharmacy collection point, such as Punto SIGRE, for safe environmental waste management. This instruction applies to both the remaining medicine and the empty primary packaging.